Complete Economic Evaluation of Nintedanib (Vargatef®) Plus Docetaxel as a Second-Line Treatment in Patients with Non-Small Cell Lung Cancer in Mexico
Abstract
Authors
J Diaz Martínez H Soto FB Baez-Revueltas S Herran LA Gonzalez-Nieto